Schizophrenia :: Vanda’s schizophrenia drug iloperidone proved effective

Vanda Pharmaceuticals Inc., The Rockville, Maryland-based company, said its experimental schizophrenia drug proved effective in a late-stage clinical trial, reviving hopes for a product that many had considered dead and sending the company’s shares soaring more than 68 percent.

Patients taking the drug, iloperidone, experienced a statistically significant improvement in symptoms compared with those taking a placebo, a result that was not always achieved in earlier trials.

The company, which went public in April, reported a successful Phase III study for its schizophrenia drug iloperidone, setting it up to file a new drug application (NDA) with the Food & Drug Administration next year. The news arrived less than a month after Vanda announced another successful late stage trial for an insomnia medication, VEC-162.

Iloperidone, which Vanda licensed from Novartis, is used to treat patients with schizophrenia. The drug was found to significantly improve schizophrenic symptoms when compared to a placebo during a four-week trial of 604 people.


Leave a Comment